PE20141685A1 - Novedosas dihidropirimidinoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de transtornos inflamatorios - Google Patents

Novedosas dihidropirimidinoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de transtornos inflamatorios

Info

Publication number
PE20141685A1
PE20141685A1 PE2014000988A PE2014000988A PE20141685A1 PE 20141685 A1 PE20141685 A1 PE 20141685A1 PE 2014000988 A PE2014000988 A PE 2014000988A PE 2014000988 A PE2014000988 A PE 2014000988A PE 20141685 A1 PE20141685 A1 PE 20141685A1
Authority
PE
Peru
Prior art keywords
treatment
pharmaceutical compositions
inflammatory disorders
alkyl
dihydropyrimidinoisoquinolinones
Prior art date
Application number
PE2014000988A
Other languages
English (en)
Spanish (es)
Inventor
Frederic Gilbert Labeguere
Gregory John Robert Newsome
Luke Jonathan Alvey
Laurent Raymond Maurice Saniere
Stephan Robert Fletcher
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Nv filed Critical Galapagos Nv
Publication of PE20141685A1 publication Critical patent/PE20141685A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PE2014000988A 2011-12-22 2012-12-20 Novedosas dihidropirimidinoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de transtornos inflamatorios PE20141685A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161578979P 2011-12-22 2011-12-22

Publications (1)

Publication Number Publication Date
PE20141685A1 true PE20141685A1 (es) 2014-11-25

Family

ID=47520068

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014000988A PE20141685A1 (es) 2011-12-22 2012-12-20 Novedosas dihidropirimidinoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de transtornos inflamatorios

Country Status (34)

Country Link
US (5) US8927543B2 (enExample)
EP (3) EP2794604B1 (enExample)
JP (1) JP6062453B2 (enExample)
KR (1) KR102012268B1 (enExample)
CN (1) CN103998448B (enExample)
AR (1) AR089284A1 (enExample)
AU (1) AU2012357067B2 (enExample)
BR (1) BR112014015142B1 (enExample)
CA (1) CA2859578C (enExample)
CL (1) CL2014001664A1 (enExample)
CO (1) CO7010835A2 (enExample)
CR (1) CR20140305A (enExample)
CY (2) CY1119434T1 (enExample)
DK (2) DK2794604T3 (enExample)
EA (1) EA023826B1 (enExample)
ES (2) ES2911449T3 (enExample)
HR (2) HRP20220456T1 (enExample)
HU (1) HUE12812237T4 (enExample)
IL (2) IL233212B (enExample)
IN (1) IN2014MN01033A (enExample)
LT (2) LT2794604T (enExample)
MX (1) MX351681B (enExample)
NI (1) NI201400060A (enExample)
PE (1) PE20141685A1 (enExample)
PH (1) PH12014501178B1 (enExample)
PL (2) PL3378862T3 (enExample)
PT (2) PT3378862T (enExample)
SG (1) SG11201403169PA (enExample)
SI (2) SI3378862T1 (enExample)
TW (1) TWI567073B (enExample)
UA (1) UA111767C2 (enExample)
UY (1) UY34545A (enExample)
WO (1) WO2013092791A1 (enExample)
ZA (1) ZA201404607B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2794627B1 (en) 2011-12-22 2018-09-26 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
AR089284A1 (es) 2011-12-22 2014-08-13 Galapagos Nv Dihidropirimidinoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de trastornos inflamatorios
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
EP2935262B1 (en) 2012-12-20 2017-03-15 Galapagos NV Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders (gpr84 antagonists)
GB201319677D0 (en) * 2013-11-07 2013-12-25 Eth Z Rich Cyclopropanation
GB201411241D0 (en) * 2014-06-25 2014-08-06 Galapagos Nv Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
GB201506894D0 (en) * 2015-04-23 2015-06-10 Galapagos Nv Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
JP6918957B2 (ja) * 2017-03-06 2021-08-11 上海 インスティテュート オブ マテリア メディカ、チャイニーズ アカデミー オブ サイエンシーズShanghai Institute Of Materia Medica, Chinese Academy Of Sciences Gpr84受容体拮抗剤およびその使用
EP3403649A1 (en) 2017-05-16 2018-11-21 Bayer Pharma Aktiengesellschaft Inhibitors and antagonists of gpr84 for the treatment of endometriosis
WO2019096944A1 (en) 2017-11-15 2019-05-23 Galapagos Nv Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
JOP20220156A1 (ar) 2019-12-19 2023-01-30 Bayer Ag مشتقات فوروإندازول
WO2021123394A1 (en) 2019-12-20 2021-06-24 University Of Copenhagen G protein-coupled receptor modulators and a pharmaceutical composition
JP2023553295A (ja) 2020-11-24 2023-12-21 ガラパゴス・ナムローゼ・フェンノートシャップ 線維性疾患の治療における使用のための化合物及び線維性疾患の治療方法
CA3206499A1 (en) 2021-02-02 2022-08-11 Liminal Biosciences Limited Gpr84 antagonists and uses thereof
WO2022179940A1 (en) 2021-02-23 2022-09-01 Bayer Aktiengesellschaft Furoindazole derivatives as gpr84 antagonists
CN115109072A (zh) * 2021-03-18 2022-09-27 武汉人福创新药物研发中心有限公司 一种gpr84拮抗剂及其制备方法和用途
WO2022218372A1 (zh) * 2021-04-14 2022-10-20 武汉人福创新药物研发中心有限公司 一种二氢嘧啶并异喹啉酮类衍生物及用途
CA3218018A1 (en) 2021-04-29 2022-11-03 Bayer Aktiengesellschaft Furoindazole derivatives as antagonists or inhibitors of gpr84
US20250066335A1 (en) 2021-06-18 2025-02-27 University Of Copenhagen Polysubstituted 4-hydroxypyridine and 4-hydroxyquinoline derivatives as gpr84 antagonists
EP4361151A4 (en) 2021-06-21 2025-06-11 Wuhan Humanwell Innovative Drug Research and Development Center Limited Company Tricyclic compound as a GPR84 antagonist
CN115611944A (zh) 2021-07-15 2023-01-17 中国科学院上海药物研究所 不对称gpr84拮抗剂及其用途
WO2023076668A1 (en) * 2021-10-29 2023-05-04 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions and methods for treatment of cancer
GB202202297D0 (en) 2022-02-21 2022-04-06 Verona Pharma Plc Formulation production process
WO2024083705A1 (en) 2022-10-18 2024-04-25 Bayer Aktiengesellschaft Furoindazole derivatives for the treatment of pain
CN120569392A (zh) * 2022-12-30 2025-08-29 广州市联瑞制药有限公司 三环类化合物及其制备方法和应用
WO2024220480A2 (en) * 2023-04-17 2024-10-24 The Board Of Trustees Of The Leland Stanford Junior University Method for detecting innate immune action in vivo using gpr84-pet
US12194045B1 (en) 2023-06-26 2025-01-14 Verona Pharma Plc Particulate composition

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2720085A1 (de) 1977-05-05 1978-11-16 Hoechst Ag Pyrimido(6,1-a)isochinolin-2-on- derivate
ATE311884T1 (de) * 1997-07-12 2005-12-15 Cancer Rec Tech Ltd Cyclin-abhängige-kinase inhibierende purinderivate
EP1165556A1 (en) * 1999-03-31 2002-01-02 Vernalis Limited Derivatives of pyrimido[6,1-a]isoquinolin-4-one
WO2005007092A2 (en) * 2003-07-08 2005-01-27 Smithkline Beecham Corporation Novel chemical compounds
WO2005050225A2 (en) 2003-10-31 2005-06-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 84 (gpr84)
WO2007027661A2 (en) 2005-09-02 2007-03-08 Arena Pharmaceuticals, Inc. Human g protein-coupled receptor and modulators thereof for the treatment of atherosclerosis and atherosclerotic disease and for the treatment of conditions related to mcp-1 expression
US7989461B2 (en) 2005-12-23 2011-08-02 Amgen Inc. Substituted quinazolinamine compounds for the treatment of cancer
US8217177B2 (en) * 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
KR20110046514A (ko) 2008-07-31 2011-05-04 제넨테크, 인크. 피리미딘 화합물, 조성물 및 사용 방법
JP2011088847A (ja) * 2009-10-21 2011-05-06 Takeda Chem Ind Ltd 三環性化合物およびその用途
CA2860192C (en) 2011-12-22 2020-10-27 Connexios Life Sciences Pvt. Ltd. Derivatives of aza adamantane and uses thereof
CA2859764C (en) 2011-12-22 2019-12-31 Novartis Ag Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives
KR102083040B1 (ko) 2011-12-22 2020-02-28 커넥시오스 라이프 사이언시즈 피브이티. 리미티드 11-베타-하이드록시스테로이드 탈수소효소의 저해제로서 사이클릭 아마이드 유도체 및 이의 용도
AR089284A1 (es) 2011-12-22 2014-08-13 Galapagos Nv Dihidropirimidinoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de trastornos inflamatorios
EP2935262B1 (en) 2012-12-20 2017-03-15 Galapagos NV Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders (gpr84 antagonists)

Also Published As

Publication number Publication date
CO7010835A2 (es) 2014-07-31
WO2013092791A1 (en) 2013-06-27
BR112014015142A2 (pt) 2017-06-13
ES2643379T3 (es) 2017-11-22
NZ626473A (en) 2016-03-31
JP6062453B2 (ja) 2017-01-18
NI201400060A (es) 2015-04-27
EA201491245A1 (ru) 2014-10-30
MX351681B (es) 2017-10-25
TWI567073B (zh) 2017-01-21
KR20140117427A (ko) 2014-10-07
CY1119434T1 (el) 2018-03-07
HRP20171404T1 (hr) 2017-11-17
US20220227751A1 (en) 2022-07-21
SI3378862T1 (sl) 2022-05-31
PH12014501178A1 (en) 2014-10-20
CA2859578A1 (en) 2013-06-27
PL2794604T3 (pl) 2017-12-29
DK3378862T3 (da) 2022-04-11
US20130165437A1 (en) 2013-06-27
ES2643379T9 (es) 2018-01-05
HUE12812237T4 (hu) 2017-12-28
ZA201404607B (en) 2020-02-26
AU2012357067A1 (en) 2014-07-10
KR102012268B1 (ko) 2019-08-21
US10047083B2 (en) 2018-08-14
CY1125167T1 (el) 2024-09-20
US8927543B2 (en) 2015-01-06
EA023826B1 (ru) 2016-07-29
IL233212B (en) 2018-03-29
AR089284A1 (es) 2014-08-13
TW201331201A (zh) 2013-08-01
IL257581A (en) 2018-04-30
US20160244442A1 (en) 2016-08-25
LT2794604T (lt) 2017-10-25
PH12014501178B1 (en) 2014-10-20
PT3378862T (pt) 2022-04-11
CR20140305A (es) 2014-07-23
IN2014MN01033A (enExample) 2015-05-01
UA111767C2 (uk) 2016-06-10
ES2911449T3 (es) 2022-05-19
EP4019519A1 (en) 2022-06-29
HRP20220456T1 (hr) 2022-05-27
HK1201528A1 (en) 2015-09-04
AU2012357067B2 (en) 2017-01-05
US20190002458A1 (en) 2019-01-03
PT2794604T (pt) 2017-10-23
EP3378862A1 (en) 2018-09-26
SI2794604T1 (sl) 2017-12-29
EP2794604A1 (en) 2014-10-29
LT3378862T (lt) 2022-04-25
JP2015500861A (ja) 2015-01-08
CN103998448A (zh) 2014-08-20
CL2014001664A1 (es) 2014-10-03
IL233212A0 (en) 2014-08-31
DK2794604T3 (da) 2017-11-06
MX2014007363A (es) 2014-08-01
CA2859578C (en) 2020-03-10
PL3378862T3 (pl) 2022-05-16
SG11201403169PA (en) 2014-07-30
BR112014015142B1 (pt) 2022-03-29
EP2794604B1 (en) 2017-09-13
CN103998448B (zh) 2016-04-20
US20140121204A1 (en) 2014-05-01
UY34545A (es) 2013-07-31
US11220499B2 (en) 2022-01-11
US9255095B2 (en) 2016-02-09
EP3378862B1 (en) 2022-03-16

Similar Documents

Publication Publication Date Title
PE20141685A1 (es) Novedosas dihidropirimidinoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de transtornos inflamatorios
EA201390969A1 (ru) Модуляторы глюкагонового рецептора
PE20141582A1 (es) Pirimidinas anilladas sustituidas y uso de las mismas
BR112012013431A2 (pt) composto, composição farmacêutica e seu uso
NI201300111A (es) Derivados de pirazoloespirocetona para uso como inhibidores de acetil-coa carboxilasa
EA201101026A1 (ru) Ингибиторы бета-секретазы
CY1119499T1 (el) Ενωσεις 6,7-διυδροπυραζολο[1,5-α]πυραζιν-4(5η)-ονης και η χρηση τους ως αρνητικοι αλλοστερικοι τροποποιητες των υποδοχεων mglur2
ECSP077424A (es) Derivados de quinuclidina y su uso como antagonistas del receptor muscarínico m3
MX390264B (es) Antagonistas d2, metodos de sintesis y metodos de uso.
PH12012501800A1 (en) 2,3 dihydro- 1h - inden- 1 - yl -2,7 -diazaspirol [ 3.5 ] nonane derivatives and their use as antagonists or inverse agonists of the ghrelin receptor
PE20142340A1 (es) Inhibidores de bromodominios
EA201490912A1 (ru) Производные [1,2,3]триазоло[4,5-d]пиримидина в качестве агонистов каннабиноидного рецептора 2
EA201290940A1 (ru) Новые соединения как селективные антагонисты рецептора nk3, фармацевтическая композиция и методы их использования при нарушениях, опосредованных nk3 рецепторами
PE20141598A1 (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
EA201390723A1 (ru) Аминозамещенные производные бисфенилпентановой кислоты в качестве ингибиторов nep
CO6700831A2 (es) Derivados de pirazina como bloqueadores de enac
PE20141380A1 (es) Imidazopiridazinas como inhibidores de quinasa akt
EA201300436A8 (ru) Совместные кристаллы и соли ингибиторов ccr3
EA201101621A1 (ru) Производные бензоксазолона в качестве ингибиторов альдостеронсинтазы
MX373079B (es) Uso de antagonistas del receptor de ep4 en el tratamiento de enfermedad de cartílago.
EA201400822A1 (ru) Производные гетероциклических амидов в качестве антагонистов p2xрецептора
EA201101301A1 (ru) Натриевая соль 5-циклопропил-2-{[2-(2,6-дифторфенил)пиримидин-5-ил]амино}бензойной кислоты в качестве ингибиторов dhodh
PE20142244A1 (es) Inhibidores de pirazolopirimidinilo de enzima activadora de ubiquitina
EA201391524A1 (ru) Производные гликозида и их применение
UY33824A (es) ?moduladores del receptor del glucagón?.

Legal Events

Date Code Title Description
FG Grant, registration